



NIAGARA REGIMEN FOR MUSCLE INVASIVE BLADDER CANCER (MIBC):

Neoadjuvant IMFINZI + gem-cis followed by adjuvant
IMFINZI monotherapy after radical cystectomy^{1,2}



NOW PBS LISTED³

**STREAMLINED
AUTHORITY LISTING**

**PBS
ELIGIBILITY
CRITERIA³**

View the full PBS criteria
(neoadjuvant and adjuvant use)

CLICK HERE

**Private
hospital PBS
item code:
15283J**

**Public
hospital PBS
item code:
15292W**

INITIAL TREATMENT – NEOADJUVANT SETTING³

Population criteria:

- Patient must be initiating treatment with this drug for this condition; **OR** patient must be transitioning from non-PBS to PBS subsidised treatment with this drug for this condition

Clinical criteria:

- The condition must not have previously been treated with systemic therapy for MIBC at the time this drug was initiated for this condition **AND**
- The treatment must be once in a lifetime with this drug for this condition **AND**
- The condition must be MIBC with both (i) clinical tumour stage of either T2, T3 or T4a (ii) nodal status of up to stage N1 **AND**
- The treatment must be for neoadjuvant use in a patient preparing for radical cystectomy **AND**
- Patient must have/have had at the time of initiating treatment with this drug a WHO PS \leq 1 **AND**
- The treatment must be/have been initiated with both: (i) gemcitabine, (ii) cisplatin **AND**

Treatment criteria:

- Patient must not be undergoing PBS subsidised treatment where this prescription extends treatment beyond whichever comes first: (i) 4 cycles from treatment initiation, irrespective of whether initial treatment was PBS subsidised/non-PBS subsidised, (ii) disease progression or recurrence despite treatment with this drug, (iii) unacceptable toxicity; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs



NIAGARA REGIMEN FOR MUSCLE INVASIVE BLADDER CANCER (MIBC):

Noadjuvant IMFINZI + gem-cis followed by adjuvant IMFINZI monotherapy after radical cystectomy^{1,2}



NOW PBS LISTED³

PBS Information: Authority required (STREAMLINED):
Refer to PBS Schedule for full information.

Please review full Product Information before prescribing, available on request from AstraZeneca on 1800 805 342 or www.astrazeneca.com.au/PI



Scan here to access the Product Information

gem-cis, gemcitabine-cisplatin; MIBC, muscle invasive bladder cancer; PBS, Pharmaceutical Benefits Scheme; RC, radical cystectomy; WHO PS, World Health Organization Performance Status. **References:** **1.** IMFINZI® (durvalumab) Approved Product Information. **2.** Powles T et al. *N Engl J Med* 2024;391(19):1773-1786. **3.** Pharmaceutical Benefits Scheme www.pbs.gov.au Accessed April 2026.

IMFINZI® is a registered trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via <https://contactazmedical.astrazeneca.com>. AU-24626. IMFN0018/EMBC. Date of preparation: April 2026